專欄詠竹坊

Biogene gets bruised in ‘battle of the skincare belles’

A squabble involving false advertising claims by a sinking Bloomage Biotech against highflying rival Giant Biogene has captivated China, with no end in sight

This article only represents the author's own views.

A fight between skincare brands owned by two of China’s wealthiest women has mesmerized the country with saturation media coverage – and left one of the pair’s formerly highflying stocks badly bruised.

In nearly a month since the skirmish began on May 17, shares of Giant Biogene Holding Co. Ltd. (2367.HK) have shed nearly 30% of their value, while Bloomage BioTechnology Corp. Ltd. (688363.SH), which initiated the dust-up, is up about 7%.

您已閱讀8%(492字),剩餘92%(5675字)包含更多重要資訊,訂閱以繼續探索完整內容,並享受更多專屬服務。
版權聲明:本文版權歸FT中文網所有,未經允許任何單位或個人不得轉載,複製或以任何其他方式使用本文全部或部分,侵權必究。
設置字型大小×
最小
較小
默認
較大
最大
分享×